The total return over the past 12 months is +30.93% vs. +19.98% for the S&P 500. So far it's up +25.46% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +30.93% | +2.03% | (14.12%) | +9.01% | +9.57% | +8.71% |
| Total Return CAGR | +30.93% | +2.03% | (14.12%) | +9.01% | +9.57% | +8.71% |
| Revenue CAGR | +1.37% | (2.21%) | +0.29% | +2.47% | +1.70% | +3.85% |
| Net Income CAGR | (30.32%) | N/A | (44.02%) | +8.64% | +1.21% | +4.45% |
| EPS CAGR | (29.17%) | N/A | (26.27%) | +22.24% | +9.97% | +11.55% |
| Free Cash Flow CAGR | +1.61% | +32.21% | (9.65%) | +16.26% | +3.84% | +10.42% |
| Operating Cash Flow CAGR | (7.78%) | +18.28% | (6.48%) | +10.12% | +3.42% | +8.75% |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Bio-Rad Laboratories, Inc. (BIO)
| Year | Start price | End price | BIO Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $302.99 | $380.12 | +25.46% | +13.55% | +11.91% |
| 2025 | $328.51 | $302.99 | (7.77%) | +17.72% | (25.49%) |
| 2024 | $322.89 | $328.51 | +1.74% | +24.89% | (23.15%) |
| 2023 | $420.49 | $322.89 | (23.21%) | +26.19% | (49.40%) |
| 2022 | $755.57 | $420.49 | (44.35%) | (18.17%) | (26.18%) |
| 2021 | $582.94 | $755.57 | +29.61% | +28.74% | +0.87% |
| 2020 | $370.03 | $582.94 | +57.54% | +18.37% | +39.17% |
| 2019 | $232.22 | $370.03 | +59.34% | +31.22% | +28.12% |
| 2018 | $238.67 | $232.22 | (2.70%) | (4.56%) | +1.86% |
| 2017 | $182.28 | $238.67 | +30.94% | +21.70% | +9.24% |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
